Elicio Therapeutics, Inc. — Form D

Elicio Therapeutics, Inc. of Boston, MA, a company, filed a Form D exempt-offering notice with the SEC on 2018-07-17. The offering totals $35.0M, of which $15.4M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (24)

NameRoleLocation
Jay D VenkatesanDirectorUniondale, NY
Michael D YaminDirectorUniondale, NY
Jay D VenkatesanExecutive OfficerUniondale, NY
Yekaterina ChudnovskyDirectorLOS ANGELES, CA
Karen WilsonDirectorBoston, MA
Christopher HaqqExecutive OfficerBoston, MA
Jay VenkatesanDirectorBoston, MA
Carol AsheDirectorBoston, MA
Brian PiekosExecutive OfficerBoston, MA
Robert ConnellyDirectorBoston, MA
Robert ConnellyExecutive OfficerBoston, MA
Allen NissensonDirectorBoston, MA
Robert RuffoloDirectorBoston, MA
Peter DeMuthExecutive OfficerBoston, MA
Julian AdamsDirectorBoston, MA
Allen R NissensonDirectorSan Francisco, CA
Jay R VenkatesanDirectorSan Francisco, CA
Jay R VenkatesanExecutive OfficerSan Francisco, CA
Karen R WilsonDirectorSan Francisco, CA
Itzhak D GoldbergDirectorUniondale, NY
Itzhak D GoldbergExecutive OfficerUniondale, NY
Victor R GanziDirectorSan Francisco, CA
Gil R OmennDirectorSan Francisco, CA
Michael R YaminDirectorUniondale, NY

Other filings by this issuer (7)

FiledFormOfferingSold
2024-03-29D$6.0M$6.0M
2024-01-05D$7.0M$7.0M
2020-06-23D$40.0M$6.7M
2020-01-27D$12.0M$1.0M
2020-01-13D$12.0M$6.1M
2018-07-17D$5.4M$5.4M
2015-02-20D$15.0M$4.4M

More